Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Corbett Winegar

Orthopaedic Surgery Meridian, ID Medical Doctor

NPI 1669632386 CMS profile 923053

2960 E. St Lukes St., Suite 200, Meridian, ID 83642

Open in the dashboard

General payments

$12,460

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Corbett Winegar of Meridian, ID is reported in the CMS Open Payments database as having received $12,460 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,441 38
2024 General $2,633 56
2023 General $1,294 29
2022 General $1,380 18
2021 General $2,559 20
2020 General $1,004 13
2019 General $2,149 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corbett Winegar
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Corbett Winegar were reported at $1,441. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Corbett Winegar Orthopaedic Surgery median Middle half National median
2019 $2,149 $644 $140–$2,844 $163
2020 $1,004 $312 $75–$1,860 $114
2021 $2,559 $520 $117–$2,495 $132
2022 $1,380 $598 $128–$2,731 $149
2023 $1,294 $461 $128–$2,264 $160
2024 $2,633 $497 $134–$2,475 $164
2025 $1,441 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $8,244 170 payments
  2. Summit Surgical Corp. $1,200 1 payment
  3. Linvatec Corporation $802 5 payments
  4. Steelhead Surgical Inc $632 6 payments
  5. Zimmer Biomet Holdings, Inc. $521 9 payments
  6. Smith+Nephew, Inc. $328 3 payments
  7. Miach Orthopaedics, Inc. $181 1 payment
  8. DePuy Synthes Sales Inc. $160 4 payments
  9. Spinefrontier, Inc. $153 1 payment
  10. Davol Inc. $38 1 payment
  11. Other $201 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,904 196 payments
  2. Travel and Lodging $4,357 16 payments
  3. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $4,002 91 payments
  2. MAKO Knees, Hips $2,008 17 payments
  3. TRIATHLON $1,093 43 payments
  4. LINVATEC KNEE PRESERVATION SYSTEM $632 3 payments
  5. INSIGNIA $343 9 payments
  6. Bioinductive Implant with Arthroscopic Delivery System - Medium $314 2 payments
  7. None $268 8 payments
  8. MAKO Joint Replacement Hips, Knees $182 2 payments
  9. TRITANIUM $178 5 payments
  10. X3 $159 1 payment
  11. Other $2,298 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$92,125

Of which drugs: $1,358

Medicare patients

132

Average age 73

Services billed

964

84 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Diabetes 20%
Depression 20%
Osteoporosis 19%
Ischemic heart disease 14%
Chronic kidney disease 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 72 $52
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 88 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $5
$5 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record